title: Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
abstract: Hypereosinophilic syndrome is a myeloproliferative disorder defined by unexplained, persistent hypereosinophilia with cutaneous or systemic involvement. We describe a patient with coexistence of hypereosinophilic syndrome and bullous pemphigoid. Treatment with the novel tyrosine kinase inhibitor imatinib mesylate resulted in durable remission of hypereosinophilia and skin lesions.
authors.affiliation: Department of Dermatology, University of Freiburg Freiburg, Germany.
authors.forename: Silke C
authors.initials: SC
authors.lastname: Hofmann
authors.forename: Kristin
authors.initials: K
authors.lastname: Technau
authors.forename: Antonia M S
authors.initials: AM
authors.lastname: Müller
authors.forename: Michael
authors.initials: M
authors.lastname: Lübbert
authors.forename: Leena
authors.initials: L
authors.lastname: Bruckner-Tuderman
mesh_terms: D000368:Aged; D001549:Benzamides; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D000068877:Imatinib Mesylate; D008297:Male; D010391:Pemphigoid, Bullous / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate